Related Articles Biopharma Funds Deliver Market-Beating Returns as Valuations Snap Back Stephen Taub J.P. Morgan’s Michael Cembalest Finds ‘Warning Signs’ in Hedge Funds Michelle Celarier Outlook 2026: Take an Active Approach to Valuation Risk and Seek Opportunities to Diversify Sponsored by Schroders